Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected ...

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September Provided by GlobeNewswire May 5, 2025, 4: ...

Shares of Dianthus Therapeutics (NASDAQ:DNTH) jumped 5.8% after William Blair initiated coverage on the stock with an Outperform rating, marking the 13th buy recommendation the clinical-stage ...

Dianthus are a favourite for cottage gardens. They're often called carnations, clove pinks or just pinks, because they look like someone's used pinking shears to cut frills around the edges.

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The following table provides a quick overview ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) while maintaining a price ...